Merck & Co. Inc. (NYSE:MRK) has been sued by Bristol-Myers Squibb Co (BMY) and Ono Pharmaceutical Co., Ltd. (Japan) (OPHLY) for patent infringement of Bristol-Myers’ novel PD-1 inhibitor, Optivo. Merck recently won the US Food and Drug Administration’s (FDA) approval for its own PD-1 drug, Keytruda. This made the company the first one to enter the US immunotherapy market, which is expected to reach $35 billion over the next decade. Merck & Co. Inc. (NYSE:MRK) belongs to Healthcare sector. Its net profit margin is 12.90% and weekly performance is 0.46%. On last trading day company shares ended up $60.76. Merck & Co. Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 3.88%.
Activision Blizzard, Inc. (NASDAQ:ATVI) said Wednesday that this week’s release of its first-person shooter videogame “Destiny” was the biggest franchise videogame launch yet, signaling the company expects its big bet on the game to pay off. Activision Blizzard, Inc. (NASDAQ:ATVI) shares moved up 0.34% in last trading session and ended the day at $23.81. ATVI Gross Margin is 65.70% and its return on assets is 5.00%. Activision Blizzard, Inc. (NASDAQ:ATVI) quarterly performance is 10.85%.
Brooks Automation (NASDAQ:BRKS) SVP William T. Montone sold 3,000 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $11.08, for a total transaction of $33,240.00. Following the completion of the sale, the senior vice president now directly owns 192,622 shares of the company’s stock, valued at approximately $2,134,252. On 10 September, Brooks Automation, Inc. (NASDAQ:BRKS) shares moved up 0.72% and was closed at $11.12. BRKS EPS growth in last 5 year was 61.80%. Brooks Automation, Inc. (NASDAQ:BRKS) year to date (YTD) performance is 8.70%.
Entergy Corporation (NYSE:ETR) has received a “BBB” credit rating from Morningstar. The credit rating agency’s “BBB” rating indicates that the company is a moderate default risk. They also issued a neutral credit outlook for the company and gave their stock a three star rating. Entergy Corporation (NYSE:ETR) ended the last trading day at $76.16. Company weekly volatility is calculated as 1.39%and price to cash ratio as 21.04. Entergy Corporation (NYSE:ETR) showed a weekly performance of -1.27%.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced a change in the Company’s presentation time at the at Aegis 2014 Healthcare & Technology Conference. President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen will present on Friday, September 12th at 10:45am Pacific Time. CytRx Corporation (NASDAQ:CYTR) shares moved up 0.59% in last trading session and ended the day on $3.39. CYTR return on assets is -67.30%. CytRx Corporation (NASDAQ:CYTR) quarterly performance is -32.47%.